Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

HERON THERAPEUTICS, INC. /DE/ Director's Dealing 2021

Jan 15, 2021

33572_dirs_2021-01-15_5d34da10-d253-4295-81de-03b56fbf22c7.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HERON THERAPEUTICS, INC. /DE/ (HRTX)
CIK: 0000818033
Period of Report: 2021-01-13

Reporting Person: Peraza Lisa (VP, Chief Accounting Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-01-13 Common Stock M 552 Acquired 11811 Direct
2021-01-13 Common Stock F 227 $18.16 Disposed 11584 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-01-13 Restricted Stock Units $ M 552 Disposed Common Stock (552) Direct

Footnotes

F1: Restricted stock units convert into common stock on a one-for-one basis.

F2: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions.

F3: The restricted stock units vest in 16 equal quarterly installments beginning three months after the date of grant (10/13/2020).